JPI-547, a Dual Inhibitor of PARP/Tankyrase, Shows Antitumor Activity Against Pancreatic Cancers with Homologous Recombination Repair Deficiency or Wnt-Addiction.

JPI-547 also showed a trend toward reducing β-catenin activation in AsPC-1 tumors in vivo , although the effect was not significant (p = 0.0791), likely due to limited sample size (Figure 4 E). qRT-PCR analyses confirmed that JPI-547 downregulated the expression of key target genes of the β-catenin pathway, Myc and AXIN2, specifically in PDAC cells with RNF43 mt (Figure 4 F).

also in 53,322 other papers